Abaxis to Report Third Quarter Fiscal 2008 Financial Results Thursday, January 31,...
* Reuters is not responsible for the content in this press release.
Abaxis to Report Third Quarter Fiscal 2008 Financial Results Thursday, January
31, 2008
UNION CITY, Calif., Jan. 22 /PRNewswire-FirstCall/ -- Abaxis, Inc.
(Nasdaq: ABAX), a medical products company manufacturing point-of-care blood
analysis systems, has scheduled a conference call to discuss its financial
results for the third quarter of fiscal year 2008, ended December 31, 2007.
The call will be at 4:15 p.m. ET, Thursday, January 31, 2008.
Participants can dial (877) 356-5706 or (706) 643-0580 to access the
conference call, or can listen via a live Internet web cast, which can be
found at http://www.abaxis.com. A replay of the call is available by visiting
http://www.abaxis.com for the next 30 days or by calling (800) 642-1687 or
(706) 645-9291, access code 32155678, through February 2, 2008.
About Abaxis
Abaxis develops, manufactures and markets portable blood analysis systems
for use in any veterinary or human patient-care setting to provide clinicians
with rapid blood constituent measurements. The system consists of a compact,
5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use
plastic discs, called reagent discs that contain all the chemicals required to
perform a panel of up to 13 tests on veterinary patients and 14 tests on human
patients. The system can be operated with minimal training and performs
multiple routine tests on whole blood, serum or plasma samples. The system
provides test results in less than 12 minutes with the precision and accuracy
equivalent to a clinical laboratory analyzer.
Contact: Clint Severson Lytham Partners, LLC
Chief Executive Officer Joe Dorame, Joe Diaz & Robert Blum
Abaxis, Inc. 602-889-9700
510-675-6500
SOURCE Abaxis, Inc.
Clint Severson, Chief Executive Officer of Abaxis, Inc., +1-510-675-6500; or
Joe Dorame, Joe Diaz & Robert Blum, all of Lytham Partners, LLC,
+1-602-889-9700, for Abaxis, Inc.
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.



Follow Reuters